A rapid and simple detection method for the BRAFTI796A mutation in fine-needle aspirated thyroid carcinoma cells

被引:51
作者
Hayashida, N
Namba, H
Kumagai, A
Hayashi, T
Ohtsuru, A
Ito, M
Saenko, VA
Maeda, S
Kanematsu, T
Yamashita, S
机构
[1] Nagasaki Univ, Grad Sch Biomed Sci, Atom Bomb Dis Inst, Dept Mol Med, Nagasaki 8528523, Japan
[2] Nagasaki Univ, Grad Sch Biomed Sci, Dept Surg, Nagasaki, Japan
[3] Nagasaki Univ, Grad Sch Biomed Sci, Int Hlth & Radiat Res, Nagasaki, Japan
[4] Nagasaki Univ Hosp, Hibakusha Med Ctr, Takashi Nagai Mem Int, Nagasaki, Japan
[5] Nagasaki Univ Hosp, Hibakusha Med Ctr, Dept Pathol, Nagasaki, Japan
[6] Natl Nagasaki Med Ctr, Dept Pathol, Omura, Japan
关键词
D O I
10.1089/thy.2004.14.910
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Fine-needle aspiration biopsy (FNAB) samples from thyroid tumor tissues were analyzed for the presence of the BRAF(T1796A) mutation by polymerase chain reaction (PCR)-restriction fragment length polymorphism (RFLP) analysis. This assay utilized a specific mismatched primer and has proved to be a relatively simple, accurate, and highly sensitive method. The analysis of 130 aspirated samples from thyroid tumors (18 follicular adenomas, 72 papillary carcinomas [PTCs], 8 follicular carcinomas, 2 undifferentiated carcinomas, 1 medullary carcinoma, 2 malignant lymphomas, and 27 adenomatous goiters) revealed BRAF(T1796A) mutations in 37 (51.4%) of 72 PTCs, supporting the usefulness of this method. We examined BRAF(T1796A) in 21 patients with thyroid tumors using leftover cells in the needle at the preoperative FNAB. BRAF(T1796A) was detected in 4 patients, of which 3 cases were diagnosed as positive and 1 case as suspicious by cytologic examination. Furthermore, BRAF(T1796A) mutations were found to occur more often in tumors of 3 cm or larger in size. Our results indicate that the preoperative determination of the presence of a BRAF(T1796A) mutation by conventional PCR-RFLP may be potentially useful in the diagnosis of the most common thyroid malignancies.
引用
收藏
页码:910 / 915
页数:6
相关论文
共 26 条
[21]   BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas [J].
Nikiforova, MN ;
Kimura, ET ;
Gandhi, M ;
Biddinger, PW ;
Knauf, JA ;
Basolo, F ;
Zhu, ZW ;
Giannini, R ;
Salvatore, G ;
Fusco, A ;
Santoro, M ;
Fagin, JA ;
Nikiforov, YE .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2003, 88 (11) :5399-5404
[22]   The Raf/MEK/ERK pathway:: new concepts of activation [J].
Peyssonnaux, C ;
Eychène, A .
BIOLOGY OF THE CELL, 2001, 93 (1-2) :53-62
[23]   IDENTIFICATION OF RAS ONCOGENE MUTATIONS IN THE STOOL OF PATIENTS WITH CURABLE COLORECTAL TUMORS [J].
SIDRANSKY, D ;
TOKINO, T ;
HAMILTON, SR ;
KINZLER, KW ;
LEVIN, B ;
FROST, P ;
VOGELSTEIN, B .
SCIENCE, 1992, 256 (5053) :102-105
[24]   IDENTIFICATION OF P53 GENE-MUTATIONS IN BLADDER CANCERS AND URINE SAMPLES [J].
SIDRANSKY, D ;
VONESCHENBACH, A ;
TSAI, YC ;
JONES, P ;
SUMMERHAYES, I ;
MARSHALL, F ;
PAUL, M ;
GREEN, P ;
HAMILTON, SR ;
FROST, P ;
VOGELSTEIN, B .
SCIENCE, 1991, 252 (5006) :706-709
[25]   BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC [J].
Soares, P ;
Trovisco, V ;
Rocha, AS ;
Lima, J ;
Castro, P ;
Preto, A ;
Máximo, V ;
Botelho, T ;
Seruca, R ;
Sobrinho-Simoes, M .
ONCOGENE, 2003, 22 (29) :4578-4580
[26]  
Xu XL, 2003, CANCER RES, V63, P4561